These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093 [TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy in the Treatment of Lung Cancer]. Fiala O; Šorejs O; Pešek M; Fínek J Klin Onkol; 2017; 30(Supplementum3):22-31. PubMed ID: 29239189 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Tripathi A; Plimack ER Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502 [TBL] [Abstract][Full Text] [Related]
7. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Bellmunt J; Powles T; Vogelzang NJ Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651 [TBL] [Abstract][Full Text] [Related]
8. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. Chism DD J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752 [TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Katz H; Wassie E; Alsharedi M Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844 [TBL] [Abstract][Full Text] [Related]
11. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754 [TBL] [Abstract][Full Text] [Related]
16. [The role of immunooncology in the treatment of urothelial cancer]. Retz M; Tauber R; Horn T Aktuelle Urol; 2017 Aug; 48(4):329-335. PubMed ID: 28591872 [TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. Gwynn ME; DeRemer DL Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors for urothelial carcinoma. Kim HS; Seo HK Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073 [TBL] [Abstract][Full Text] [Related]
20. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]